

myEvolv v10.1 Real World Testing

2022 Results Report

Prepared for

Drummond



Netsmart

www.ntst.com

11100 Nall Avenue
Overland Park, KS 66211
800.842.1973

Table of Contents

Table of Contents	1
General Information	2
[Optional] Changes to Original Plan	2
[Optional] Withdrawn Products	3
Summary of Testing Methods & Key Findings.....	3
Standards Updates ((Including Standards Version Advancement Process (SVAP) AND United States Core Data for Interoperability (USCDI))	4
Care Setting(s)	4
Metrics and Outcomes.....	5
Outcomes Explained	9
§170.315(b)(1) – Transitions of Care	9
§170.315(b)(2) – Clinical Information Reconciliation and Incorporation.....	9
§170.315(b)(3) – Electronic Prescribing	10
§170.315(b)(6) – Data Export.....	11
§170.315(c)(1) – Clinical Quality Measures (CQMs) – Record and Export.....	11
§170.315(c)(2) – Clinical Quality Measures (CQMs) – Import and Calculate.....	12
§170.315(c)(3) – Clinical Quality Measures (CQMs) – Report.....	12
§170.315(e)(1) – View, Download, and Transmit to 3 rd Party	13
§170.315(f)(1) – Transmission to Immunization Registries.....	13
§170.315(f)(2) – Transmission to Public Health Agencies- Syndromic Surveillance	14
§170.315(g)(7) – Application Access – Patient Selection	15
§170.315(g)(8) – Application Access – Data Category Request.....	15
§170.315(g)(9) – Application Access- All Data Request	16
§170.315(h)(1) – Direct Project	16
Schedule of Key Milestones	17
Attestation	17

General Information

Plan Report ID Number: [For ONC-Authorized Certification Body use only]

Developer Name: Netsmart Technologies

Product Name(s): myEvolv Certified Edition

Version Number(s): 11

Certified Health IT Product List (CHPL) ID(s): 15.04.04.2816.myEv.11.02.0.221227

Developer Real World Testing Page URL: <https://www.ntst.com/lp/certifications>

[Optional] Changes to Original Plan

If a developer has made any changes to their approach for Real World Testing that differs from what was outlined in their plan, note these changes here.

Summary of Change [Summarize each element that changed between the plan and actual execution of Real World Testing]	Reason [Describe the reason this change occurred]	Impact [Describe what impact this change had on the execution of your Real World Testing activities]
Time periods for the following criteria changed: (b)(1), (c)(1)-(c)(3), (g)(7)-(g)(9), (h)(1).	Change was due to an analysis of the data. It was determined there is not a need for yearlong or 90-day reporting periods due to breadth of data provided in the shortened durations.	No impact on the results of our Real World Testing activities.
Utilization of testing tools for some criterion.	Some criterions did not product Real World results because no clients were utilizing the criterion.	We utilized testing tools to verify compliance with the criterion.

[Optional] Withdrawn Products

If a developer withdrew any products within the past year that were previously included in their Real World Testing plan, please provide the following information.

Product Name(s):	myEvolv Certified Edition
Version Number(s):	10.1
CHPL Product Number(s):	15.04.04.2816.myEv.10.01.0.180828
Date(s) Withdrawn:	12/31/2022
Inclusion of Data in Results Report: [Provide a statement as to whether any data was captured on the withdrawn products. If so, this data should be identified in the results report.]	The data captured for the purposes of this Results Report was drawn from this version of the product.

Summary of Testing Methods & Key Findings

Consistent with the ONC’s recommendation that “Real World Testing verify that deployed Certified Health IT continues to perform as intended by conducting and measuring observations of interoperability and data exchange”, Netsmart’s original test plan focused on capturing and documenting the ability of certified capabilities to be successfully utilized in the real world.

To demonstrate real-world interoperability, Netsmart compiled end user data through calculated feedback automation, based on the number of instances a specific action is performed in the solution software. This approach did not require the end user to be actively involved in testing.

When no evidence existed due to zero adoption of a certified capability, we tested and demonstrated the required certified capability in a semi-controlled setting as close to a “real world” implementation as possible.

Standards Updates ((Including Standards Version Advancement Process (SVAP) AND United States Core Data for Interoperability (USCDI))

Both required and voluntary standards updates must be addressed in the Real World Testing plan. Real World Testing plans must include all certified health IT updated to newer versions of standards prior to August 31 of the year in which the updates were made. Indicate as to whether optional standards, via SVAP and/or USCDI, are leveraged as part of the certification of your health IT product(s).

- Yes, I have products certified with voluntary SVAP or USCDI standards. (If yes, please complete the table below.
- No, none of my products include these voluntary standards

The Netsmart myEvolv certified product is not and has not participated in the Standards Version Advancement Process prior to August 31, 2021.

Standard (and version)	N/A
Updated certification criteria and associated product	N/A
CHPL Product Number	N/A
Conformance measures	N/A

Care Setting(s)

myEvolv supports the deployment and tracking of documentation within and outside of the behavioral health care specialty setting. This care setting comprises largest care setting among Netsmart’s user base. Behavioral health specialties include the following: Psychology, Psychiatry, Addiction, and Pain Management. The majority of services are performed in the outpatient setting.

Metrics and Outcomes

Associated Criteria	Measurement /Metric	Relied Upon Software (if applicable)	Outcomes	Challenges Encountered (if applicable)
170.315(b)(1) Transitions of care	Over a 30-day period: 1)Number of XDR/XDM referral messages sent within a 90-day period. (CareConnect Inbox) 2)Number of XDR/XDM referral messages received withing a 90-day period. (CareConnect Inbox) 3)Number of successful CCD retrievals from external organizations within a 90-day period. (Carequality) 4)Number of successful CCDs provided to external organizations within a 90-day period. (Carequality)	CareConnect Inbox, a Netsmart solution. And CareQuality.	1) 16 2) 1 3) 567 4) 30	Reduced the original reporting period from 90 days to 30 days.
170.315(b)(2) Clinical information reconciliation and incorporation	Over a 12-month period: 1)Numerator: Number of Clinical Reconciliations completed 2)Denominator: Number of unique Patients with a completed Clinical Reconciliation	N/A	1) 1077 2) 655	There were no challenges encountered when testing and collecting data for these criteria.
170.315(b)(3) Electronic prescribing	Over a 12-month period <ul style="list-style-type: none"> • Number of e-prescriptions sent over number of e-prescriptions successfully received. <ul style="list-style-type: none"> ○ Numerator: # of prescriptions with a chosen output of eRx (e.g., send electronically) ○ Denominator: # of prescriptions successfully sent electronically (Successfully accepted by Ultimate Receiver) • Electronic Prescribing: Request and respond to change prescriptions <ul style="list-style-type: none"> ○ Numerator: # of RxChange Requests responded to (approve and deny) and sent eRx ○ Denominator: # of ChangeRx requests successfully sent electronically (RxChangeResponse) 	OrderConnect, a Netsmart solution.	<ul style="list-style-type: none"> • Number of e-prescriptions sent over number of e-prescriptions successfully received. <ul style="list-style-type: none"> ○ Numerator: 1918046 ○ Denominator: 1855296 • Electronic Prescribing: Request and respond to change prescriptions <ul style="list-style-type: none"> ○ Numerator: 3304 ○ Denominator: 1579 • Electronic Prescribing: Request and respond to cancel prescriptions <ul style="list-style-type: none"> ○ Numerator: 284550 ○ Denominator: 159292 	There were no challenges encountered when testing and collecting data for these criteria. No clients have turned on their RxFill feature as of this reporting.

	<ul style="list-style-type: none"> • Electronic Prescribing: Request and respond to cancel prescriptions <ul style="list-style-type: none"> ○ Numerator: # of CancelRx prescriptions (e.g., discontinue) with a chosen output of eRx ○ Denominator: # of CancelRx prescriptions successfully sent electronically (CancelRxResponse) • Electronic Prescribing: Request and respond to renew prescriptions <ul style="list-style-type: none"> ○ Numerator: # of RxRenewal Requests responded to (approve and deny) and sent eRx ○ Denominator: # of RxRenewal requests successfully sent electronically (RxRenewalResponse) • Electronic Prescribing: Receive fill status notifications <ul style="list-style-type: none"> ○ Numerator: # of RxFill status requests sent to pharmacies ○ Denominator: # of RxFill status responses received from pharmacies • Electronic Prescribing: Request and receive medication history <ul style="list-style-type: none"> ○ Numerator: # of medication history requests made (RxHistoryRequest) ○ Denominator: # of medication history responses received (RxHistoryResponse) 		<ul style="list-style-type: none"> • Electronic Prescribing: Request and respond to renew prescriptions <ul style="list-style-type: none"> ○ Numerator: 157538 ○ Denominator: 103777 • Electronic Prescribing: Receive fill status notifications <ul style="list-style-type: none"> ○ Numerator: 0 ○ Denominator: 0 • Electronic Prescribing: Request and receive medication history <ul style="list-style-type: none"> ○ Numerator: 21452 ○ Denominator: 17516 	
170.315(b)(6) Data export	<p>Over a 12-month period:</p> <ol style="list-style-type: none"> 1) Numerator: # of scheduled batch jobs for patient data export summaries 2) Denominator: # of total patient data export summaries generated 	N/A	<ol style="list-style-type: none"> 1) 112 2) 168 	There were no challenges encountered when testing and collecting data for these criteria.
170.315(c)(1-3) Clinical quality measures (CQMs)	<p>Over a 6-month period:</p> <p>Metric for (c)(1)</p> <ul style="list-style-type: none"> ○ Numerator: Number of transactions written from CareRecord ○ Denominator: Number of unique CareRecord Instances that submitted transactions <p>Metric for (c)(2)</p> <ul style="list-style-type: none"> • Numerator: Sum of CQMs calculated on imported patients • Denominator: Number of unique patients imported <p>Metric for (c)(3)</p>	CarePathways, a Netsmart measures reporting solution.	<p>C1:</p> <p>Tested 1/1/2022 – 6/30/2022</p> <p>Numerator: Number of transactions written from the CareRecord: 185,837,259</p> <p>Denominator: Number of Unique instances that submitted transactions: 252</p> <p>C2:</p> <p>Tested 7/30/2022 – 12/31/2022</p>	There were no challenges encountered when testing and collecting data for these criteria.

	<ul style="list-style-type: none"> Numerator: Number of Clients (Agencies) to export a QRDA CAT-III File Denominator: Number of Clients (Agencies) to generate a QRDA CAT-III File 		<p>Numerator: Number of CQMs calculated on imported patients: 0</p> <p>Denominator: Number of Unique patients imported: 0</p> <p>C3:</p> <p>Tested 7/30/2022 – 12/31/2022</p> <p>Numerator: Number of agencies to export a CAT III file: 1</p> <p>Denominator: Number of agencies to generate a CAT III file: 1</p>	
170.315(e)(1) View, download, and transmit to 3rd party	<p>Over a 12-month period:</p> <ol style="list-style-type: none"> View Chart summary <ul style="list-style-type: none"> Numerator: # of views of the chart summary Denominator: # of clients that had an encounter during the reporting period Download of chart summary <ul style="list-style-type: none"> Numerator: # of downloads of chart summary Denominator: # of clients that had an encounter during the reporting period Transmission of chart summary <ol style="list-style-type: none"> Numerator: # of transmissions of chart summary Denominator: # of clients that had an encounter during the reporting period 	Intellichart	<ol style="list-style-type: none"> View Chart summary <ul style="list-style-type: none"> Numerator: # 31 Denominator: # 6540 Download of chart summary <ul style="list-style-type: none"> Numerator: # of 2 Denominator: # 6540 Transmission of chart summary <ul style="list-style-type: none"> Numerator: # 2 Denominator: # 6540 	There were no challenges encountered when testing and collecting data for these criteria.
170.315(f)(1) Transmission to Immunization Registries	<p>Over a 12-month period:</p> <ol style="list-style-type: none"> Numerator: Number of distinct immunization records in the denominator that sent recorded immunizations to an immunization registry Denominator: Number of distinct immunization records in a given month period 	N/A	<ol style="list-style-type: none"> 47142 809655 	There were no challenges encountered when testing and collecting data for these criteria
170.315(f)(2) Transmission to Public Health	<p>Over a 12-month period:</p> <ol style="list-style-type: none"> Numerator: Number of distinct syndromic surveillance records in the denominator that sent syndromic 	N/A	<ol style="list-style-type: none"> 0 0 	There were no challenges encountered when testing and

Agencies-Syndromic Surveillance	surveillance records to a public health agency 2) Denominator: Number of distinct syndromic surveillance records in a given month period			collecting data for these criteria
170.315(g)(7) Application access — patient selection	Over a 30-day period: 1) Number of Patient searches conducted using the FHIR R4 Patient endpoint during a 90-day window.	N/A	1) 0	Reduced the original reporting period from 90 days to 30 days.
170.315(g)(8) Application access — data category request	Over a 30-day period: 1) Number of successful requests to the FHIR R4 endpoints excluding Patient and DocumentReference within a 90-day period.	N/A	1) 0	Reduced the original reporting period from 90 days to 30 days.
170.315(g)(9) Application access — all data request	Over a 30 day period: 1) Number of successful CCD retrievals using either the certified CCD or the FHIR R4 DocumentReference endpoints within a 90-day period.	N/A	1) 0	Reduced the original reporting period from 90 days to 30 days.
170.315(h)(1) Direct Project	Over a 30 day period: 1) Number of XDR/XDM direct message sent and received by type within a 90-day period.	N/A	1) 53591	Reduced the original reporting period from 90 days to 30 days.

Outcomes Explained

§170.315(b)(1) – Transitions of Care

Outcomes Explained

A query was performed on audit logs for the 2022 year. The totals demonstrate providers and patients (or their authorized representatives) ability to share EHI using the transmission mechanisms provided. Error rates were tracked and trended over time. Specifically, the measurements selected demonstrate that referral messages can successfully be exchanged with external organizations using XDR/XDM direct messages. The measurements also show that an organization may successfully exchange CCDs upon request utilizing the Carequality network.

Justification & Test Methodology

Logs were reviewed to determine the frequency and the transport mechanism used by providers for sending/receiving transitions of care using Edge protocols. Log files obtained during Real World Testing were de-identified and used for analysis in several areas to validate the proper operation of the transport mechanisms and input for the calculation of the measure on the specific types of transport mechanisms used. This test methodology primarily tests the conformance of the implementation.

§170.315(b)(2) – Clinical Information Reconciliation and Incorporation

Outcomes Explained

A query on historical audit logs from our centralized platform for a 30-day period was performed. The total demonstrates our end user's ability to utilize Clinical Information Reconciliation & Incorporation to ingest data from transitions of care/referrals.

Justification & Test Methodology

Clinical Information Reconciliation may be completed multiple times in a given period on a single patient. This measure demonstrates the volume from both an end-user perspective (Numerator), and a Patient perspective (Denominator).

Our platform utilizes a centralized platform for these transactions, with logging, monitoring, and reporting capabilities. We reported on these measures from the data made available by this centralized platform.

§170.315(b)(3) – Electronic Prescribing

Outcomes Explained

As expected, our log files showed an increase in successful e-prescribing transactions. The outcome for RxFill is at 0 because our myEvolv care record clients have not yet adopted the functionality. Regarding medication history requests, we have seen an uptick in prescriber adoption of it and expect to see more given an improved response rate since a Surescripts upgrade for med history. Our RxChange and Renewal usage rates were not surprising. We are finding that while some prescribers greatly appreciate the feature others find it bothersome. We continue to work on educating our prescribers as to the value of these features in assisting with patient medication compliance.

Justification & Methodology

E-prescribing has been shown repeatedly to increase patient adherence to medications. As such, more and more states are requiring providers use e-prescribing. To fully receive the benefits of e-prescribing a prescriber should be able to send and receive information to and from pharmacies. This information is in the form of the proposed measures. The proposed measures will demonstrate the ability to send new prescriptions, receive renewal requests and change requests, and discontinues (cancel requests). In addition, the ability to receive a patient's medication fill history and external medication history increases medication adherence and decreases the prospect of drug overuse, abuse, and polypharmacy.

After transactions are sent from our system to Surescripts (and then to the pharmacy) the Surescripts network sends messages back to our system indicating if they were or were not successful. During testing we will review our logs to ensure all prescribing transactions that are sent to the Surescripts network are successfully received. This includes transaction requests to receive Rx Fill data and Medication History.

§170.315(b)(6) – Data Export

Outcomes Explained

A query on historical audit logs for the 2022 year was performed. The totals demonstrate the ability to view the number of patient data export summaries generated via a schedule in relation to the total number of patient data export summaries generated.

Justification & Test Methodology

The measurement selected demonstrates providers can generate a batch of CCDs for given criteria for a subset of their client population. In addition, this measurement will demonstrate the ability to schedule batch patient data export for generation.

Log files will provide audit of batches generated and user access. Database tables within the certified product application contain a record of all scheduled jobs created. If there's no record of client usage, then we will utilize internal testing systems to demonstrate the ability to generate batch patient data export summaries.

§170.315(c)(1) – Clinical Quality Measures (CQMs) – Record and Export

Outcomes Explained

End Users recorded EHI in the System and had that data available for use in calculation of CQM Results.

Justification & Test Methodology

The Measures Reporting System i.e., Care Pathways, includes two functionalities of interest: (A) Recording transactions entered into the System, and (B) calculating CQM results based on the recorded transactions. This measure provides information on the volume of transactions recorded, and the breadth of our client base utilizing this functionality.

Our platform utilizes a centralized platform for these transactions, with logging, monitoring, and reporting capabilities. We reported on these measures from the data made available by this centralized platform.

§170.315(c)(2) – Clinical Quality Measures (CQMs) – Import and Calculate

Outcomes Explained

An Import of QRDA CAT-I files into Measures Reporting System was performed. Data was processed, and any potential duplicates removed. Results were generated across multiple CQMs.

Justification & Test Methodology

Our Measures Reporting System, Care Pathways, utilizes an internal protocol to share information between systems, therefore it is not necessary for our system to specifically use the QRDA CAT-I file for use on a day-to-day basis. For this reason, no results for the use of this functionality were identified during the measurement window. We did complete testing using the Cypress tool to confirm functionality was accessible should an agency choose to use this workflow over the optimized and integrated internal protocol

We utilized Cypress to generate QRDA CAT-I files for import, and generate results based on that clinical data, across multiple CQMs.

§170.315(c)(3) – Clinical Quality Measures (CQMs) – Report

Outcomes Explained

Agencies calculated CQM results on a frequent basis, however, only exported their QRDA CAT-III file on an annual basis.

Justification & Test Methodology

The Measures Reporting System, Care Pathways, will generate a QRDA CAT-III on demand as part of the functionality within the solution, however Agencies will only utilize that file when the results are required to upload into QPP and/or State-based portals. Since the monitoring period fell outside of the MIPS submission window agency utilization of this feature was low as it is not required for their day-to-day operational needs of the platform.

Internal tooling is available for monitoring and reporting QRDA CAT-III file generation and exporting, to track how many agencies are utilizing our measures on a day-to-day basis vs. when they are being used to attest with generated CAT-III files. Reporting is available to calculate this measure.

§170.315(e)(1) – View, Download, and Transmit to 3rd Party

Outcomes Explained

It is expected that patients (or their authorized representatives) will be able to view, download and transmit their chart summaries using the mechanisms provided. Error rates will be tracked and trended over time.

The outcomes were determined by capturing the data points over 365 days with two clients that utilize a myHealthPointe connected myEvolv system. The outcomes determined that there were 31 views, 2 downloads and 2 transmissions of the chart summary.

Justification & Test Methodology

The measurements selected demonstrate that chart summaries can successfully be viewed and downloaded by patients and that they are able to successfully transmit to external parties.

We will utilize myHealthPointe (myHP), a Netsmart Product, to access data related to the ability of clients to view, download, and transmit their data to external parties. myHP utilizes log files to capture the relevant data points.

§170.315(f)(1) – Transmission to Immunization Registries

Outcomes Explained

A query on historical audit logs for 12 months was performed for this criterion. The totals demonstrate the client's ability to send data to immunization registries. We used internal testing tools to demonstrate compliance with the capability.

Justification & Test Methodology

We did not anticipate any myEvolv clients were utilizing this capability. However, we discovered during Real World Testing we had several clients who have begun utilizing this capability. We initially planned to utilize testing tools but did not have to do so.

§170.315(f)(2) – Transmission to Public Health Agencies- Syndromic Surveillance***Outcomes Explained***

A query on historical audit logs was performed for the 2022 year. We received a zero result for our numerator, and denominator, meaning none of our clients generated or the syndromic surveillance records to a public health agency. We anticipated this result for our myEvolv clients.

Justification & Test Methodology

No clients on the myEvolv certified product generated records and sent data to public health agencies for syndromic surveillance reporting. For this reason, we used testing tools to demonstrate that the capability is present should a client opt to begin sending data to public health agencies.

We utilized the NIST HL7v2 Syndromic Surveillance Test Suite to demonstrate our compliance with the certification criteria. And to demonstrate clients have a functioning ability to send syndromic surveillance data to public health agencies should they opt to do so in the future.

§170.315(g)(7) – Application Access – Patient Selection

Outcomes Explained

No myEvolv clients for the 30-day period utilized the FHIR R4 Patient endpoint to search for a patient. Adoption & utilization for this criterion is currently low to zero for our myEvolv clients.

Justification & Test Methodology

Due to the fact we had zero adoption for this criterion for the time period sampled, we utilized internal testing tools to verify compliance.

The FHIR R4 Patient endpoint will provide a variety of search parameters to support identification of a patient for subsequent searches. The searches will result in a “searchset” Bundle listing all Patients that match the provided criteria. When no matches are found an empty Bundle will be returned to the requestor. This measure will demonstrate that the search capability is available and utilized.

Internal monitoring tools provided utilization over the specified time period.

§170.315(g)(8) – Application Access – Data Category Request

Outcomes Explained

A query on historical audit logs was performed for a 30-day time period. We have zero adoption of this criterion for clients utilizing the myEvolv product.

Justification & Test Methodology

We utilized internal monitoring & testing tools to verify the capability of our FHIR R4 endpoints to read or search for patient data of the following resource types:

- AllergyIntolerance
- Condition
- Immunization
- MedicationRequest
- Observation
- Procedure
- QuestionnaireResponse

§170.315(g)(9) – Application Access- All Data Request

Outcomes Explained

We performed a query on historical logs for a 30-day time period. We have zero adoption of this criterion for clients utilizing the myEvolv product.

Justification & Test Methodology

We utilized internal monitoring & testing tools to demonstrate our solutions ability to produce a certified CCD and the FHIR R4 DocumentReference endpoint that will provide a generated CCD upon request based on the supplied parameters. Testing demonstrates that the capability is available and can be utilized should clients opt to do so.

§170.315(h)(1) – Direct Project

Outcomes Explained

We performed historical queries for a 30-day time period. The totals demonstrate the products ability to sent and receive the following types of messages during the reporting window:

- Message
- Notification
- Referral
- Referral Response

Justification & Test Methodology

This measure demonstrates the types of messages that are supported for direct messaging.

Logs were reviewed to determine the frequency and the transport mechanism used by providers for sending/receiving transitions of care using Edge protocols. Log files obtained during Real World Testing were de-identified and used for analysis in several areas to validate the proper operation of the transport mechanisms and input for the calculation of the measure on the specific types of transport mechanisms used. This test methodology will primarily test the conformance of the implementation.

Schedule of Key Milestones

Key Milestones	Care Setting(s)	Date/Timeframe
Submit Real World Testing Plan documentation to Drummond.	Behavioral health care specialty setting	November 1, 2021
Begin Collection of information as laid out by the plan for the period.	Behavioral health care specialty setting	January 1, 2022
Follow-up with providers and authorized representatives on a regular basis to understand any issues arising with the data collection.	Behavioral health care specialty setting	Quarterly, 2022
End of Real-World Testing period/final collection of all data for analysis.	Behavioral health care specialty setting	December 31, 2022
Analysis and report creation.	Behavioral health care specialty setting	January 15, 2023
Submit Real World Testing report to ACB (per their instructions)	Behavioral health care specialty setting	February 1, 2023

Attestation

This Real World Testing Results Report is complete with all required elements, including measures that address all certification criteria and care settings. All information in this Report is up to date and fully addresses the Health IT Developer's Real World Testing requirements.

Authorized Representative Name: Dru Anne Walz

Authorized Representative Email: Dwalz@ntst.com

Authorized Representative Phone: (913) 696-3477

Authorized Representative Signature:



Date: 2/1/2023